Green Cross’s Hunterase approved to conduct Phase 2 clinical trials in US

Green Cross’s rare disease therapies will challenge the U.S. market.

On the 12^th, Green Cross(CEO Eun-cheol Huh) announced recent acquisition of approval to start Phase 2 clinical trials of ‘Hunterase(project code: GC1111),’ a Hunter’s syndrome treatment from the U.S. Food and Drug Administration(FDA).

At the clinical trials Green Cross will prove efficacy and safety when increasing dosage by...